Parathyroid hormone related protein producing penile cancer.
Explore the source record for details and available documents.
Carcinoma, Squamous Cell↗
Biomedical subjects
Hideki Fuse
Publications and source records attributed to Hideki Fuse.
Development of the conditionally immortalized testicular Sertoli cell line TTE3 expressing Sertoli cell specific genes from mice transgenic for temperature sensitive simian virus 40 large T antigen gene.
PURPOSE: We developed and characterized a conditionally immortalized testicular Sertoli cell line from transgenic mice bearing the temperature sensitive simian virus 40 large T antigen gene pSVtsA58. MATERIALS AND METHODS: Established cells from 8-week-old male transgenic mice were cultured at a permissive (33C) or nonpermissive (39C) temperature on a collagen type I pre-coated culture vessel. The expression of Sertoli cell specific proteins was analyzed by reverse transcriptase-polymerase chain reaction, immunocytochemical testing and Western blot analysis. RESULTS: The Sertoli cell line TTE3 grew at 33C but not at 39C. Large T antigen was expressed only in the nuclei at 33C, indicating that the temperature sensitive growth phenotype of the cells arose as a result of the function of temperature sensitive simian virus 40 large T antigen. The cells did not show any colony forming activity in soft agar or form tumors in subcutaneous tissue in nude mice, showing that TTE3 cells were not transformed. The cells expressed messenger RNAs encoding steel factor, inhibin-alpha, transferrin, follicle-stimulating hormone receptor and sulfated glycoprotein-2. Moreover, expression of vimentin and zonula occludens-1 was observed in the cytoplasm and on the boundaries of the cells, respectively. Interestingly expression levels of transferrin and zonula occludens-1 were significantly elevated at 39C. CONCLUSIONS: TTE3 cells with these unique characteristics should serve as a useful model to study the regulation of Sertoli cell function.
Animals↗
[Chinese medicine for treatment of patients with prostatic hyperplasia].
Explore the source record for details and available documents.
Animals↗
Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer.
BACKGROUND: Tissue factor (TF), the main initiator of blood coagulation, is involved in cancer metastasis and progression. We examined the role of TF on prostate cancer. MATERIALS AND METHODS: Immunohistochemical analysis was performed using the anti-TF antibody. Intra-tumoral blood vessels were visualized by staining endothelial cells with CD34 antibody. We examined the expression of TF and the microvessel density (MVD) in 66 biopsy specimens of prostate cancer, in order to investigate the relationship between the expression of TF and the clinicopathology of prostate cancer. RESULTS: TF antigen was positive in 41 (62%) of the specimens. There were significant differences in TF expression according to the pretreatment prostate specific antigen (PSA) level (p = 0.0193) and bone metastasis (p = 0.0029). MVD was significantly related to bone metastasis (p = 0.0175). TF-positive carcinomas more frequently presented high MVD expressions (p = 0.017) than TF-negative tumors. CONCLUSION: These results suggest that increased angiogenesis associated with TF expression might cause the metastasis and progression of prostate cancer.
Aged↗
Cell proliferation, apoptosis and prognosis in patients with metastatic prostate cancer.
BACKGROUND: Since tumor growth is determined by an imbalance between cell growth and cell death, we assessed the incidence of cell proliferation and apoptosis in biopsy specimens from patients with metastatic prostate cancer treated with endocrine therapy. MATERIALS AND METHODS: In fifty-five patients with untreated metastatic prostate cancer, proliferation and apoptotic indices were determined by detection of Ki-67 immunostaining and the in situ end-labeling technique, respectively. The clinical parameters and prognosis of the patients were evaluated. RESULTS: The proliferation index in poorly-differentiated cancer was significantly higher than that in moderately-differentiated cancer. Good-responders to hormone therapy, as assessed by the decrease in prostate-specific antigen after the endocrine therapy, were likely to have a low proliferation index. The patients with a low proliferation index had better progression-free and cause-specific survival compared to those with a high proliferation index. Proliferation indices were significantly correlated with apoptotic indices. CONCLUSION: Metastatic prostate cancer shows an increase of malignant potential as assessed by the number of Ki-67-positive cells and proliferation in each tumor is correlated with apoptosis.
Aged↗
Effect of hepatocyte growth factor on invasion of prostate cancer cell lines.
Hepatocyte growth factor (HGF) was suggested to play an important role in the regulation of mitogenesis, motogenesis, angiogenesis, migration and invasion for various types of cells, and acts through a specific membrane receptor encoded by c-met proto-oncogene. However, the mechanism of the effect of HGF on tumor invasion of prostate cancer cells remains unclear. We investigated the effect of HGF on the invasion of PC-3 and DU-145 prostate cancer cells through a reconstituted basement membrane (Matrigel), the haptotactic migration to fibronectin substrate, the expression of protein and mRNA for matrix metalloproteinases (MMP)-1 and -9, membrane-type 1-MMP (MT1-MMP), urokinase-type plasminogen activator (u-PA) and its receptor (uPAR). HGF increased both Matrigel invasion and haptotactic migration of prostate cancer cells. Furthermore, HGF also increased the production of MMP-1 and -9, MT1-MMP, u-PA and uPAR of these cells. These results suggested that HGF increased the invasive potential of prostate cancer cells probably through enhancement of cell motility and the production of MMPs and u-PA.
Antineoplastic Agents↗
Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer.
BACKGROUND: Urokinase-type plasminogen activator (u-PA) has been reported to overexpress in several types of human cancers and correlate with cancer progression. The present study was performed to evaluate the significance of expression of u-PA on the progression of prostate cancer. MATERIALS AND METHODS: Expression of u-PA protein was investigated immunohistochemically on paraffin-embedded section from 61 patients with untreated prostate cancer. The correlation between the u-PA expression and clinical outcome was examined. RESULTS: u-PA was expressed in the cytoplasm of glandular cells of 56% patients. Higher expression of u-PA protein was positively correlated with bone metastasis (p = 0.011). The cause-specific survival rate was significantly lower in u-PA-positive patients than that in u-PA-negative patients (p = 0.0012). In those with bone metastasis, patients with u-PA expression had worse cause-specific survival than those without u-PA expression (p = 0.030). CONCLUSION: Increased expression of u-PA is a feature of bone metastasis in patients with prostate cancer. u-PA expression is a prognostic factor in patients with prostate cancer.
Aged↗
The effect of eicosapentaenoic acid on prostate-specific antigen.
The "Study of EPA Effects on Prostate Cancer" (SEEPC) Group has been conducting a clinical trial with patients who underwent radical prostatectomy. The main purpose of the SEEPC is to evaluate whether eicosapentaenoic acid (EPA) prevents prostate cancer (PC) recurrence. As the surrogate marker of recurrence, the prostate-specific antigen (PSA) level was measured. However, if EPA affects the PSA values independently of PC, PSA may not be a good marker of recurrence in the event of EPA treatment. Thus, in the present study, whether EPA affected the PSA values was investigated using non-PC volunteers. Twenty men, of at least 50 years of age, were recruited, mostly from hospital staff The volunteers were randomly allocated either to the EPA group or the control. The subjects in the EPA group were administered EPA-ethyl ester a dose of 2400 mg/day for 12 weeks, whereas the controls were administered none. Fasting blood samples were obtained before the start of EPA administration and 4 and 12 weeks later. The EPA concentrations in erythrocytes increased in all the subjects in the EPA group (174+/-96%) with no significant changes in the control group (8.5+/-14.0%). There were no significant differences between the two groups in the serum PSA levels, allowing the conclusion that the PSA is an appropriate surrogate marker of recurrence in prostate cancer.
Aged↗